Start here if you're new
what it is
Longeveron is a tiny biotech trying to turn one donor-derived cell therapy into treatments for heart disease, Alzheimer’s, and frailty.
how it gets paid
Last year Longeveron made $2M in revenue. HLHS program-related revenue was the main engine at $0.8M, or 40% of sales.
what just happened
Latest quarter revenue hit $834K, but the bigger truth is that losses still dwarf the sales base.
At a glance
C++ balance sheet — some cracks in the foundation
-$2.62 fy2024 eps est
$2M fy2024 rev est
n/m operating margin — loss-making; % distorts on ~$2M revenue
1.2 beta
xvary composite: 32/100 — weak
What they do
Longeveron is a tiny biotech trying to turn one donor-derived cell therapy into treatments for heart disease, Alzheimer’s, and frailty.
This company has one real advantage: regulators already gave Lomecel-B five FDA designations across two programs. FDA designations (special review perks) → the agency gives a drug extra help and faster paths → your tiny biotech gets a louder voice than its $2 million revenue suggests. With just 25 employees, that kind of regulatory traction is the closest thing this business has to leverage.
How they make money
$2M
annual revenue
HLHS program-related revenue
$0.8M
+509%
Alzheimer's program-related revenue
$0.6M
+509%
Frailty program-related revenue
$0.4M
0%
Other research and clinical activity
$0.2M
+509%
The products that matter
lead clinical asset
Lomecel-B
the core equity story
This is the asset doing the real work. If the data get cleaner and the path gets clearer, the stock changes character. If they do not, the rest of the story is mostly financing math.
main catalyst
commercial reality check
current revenue base
$2M annual revenue
Revenue is real, but it is not carrying the company. In plain English: you are not buying a scaled operating business here. You are buying time for the pipeline to prove itself.
still tiny
balance sheet constraint
cash runway
thin by design of the page
The source page does not give you a clean runway figure. That matters. In clinical biotech, missing runway detail is not a footnote. It is one of the first things you would want before getting comfortable.
what to verify
Key numbers
$2M
2024 revenue
That is the full-year 2024 revenue estimate. Plain English: the commercial base is tiny, so the stock is pricing hope more than sales.
n/m
operating margin
On ~$2M revenue and steady losses, a headline operating-margin % is easy to misread—focus on burn versus sales, not a tidy ratio.
$0M
long-term debt
Long-term debt (money owed beyond a year) → fixed financial burden → zero debt helps, but it does not solve the burn rate.
5
FDA designations
Five FDA designations across two programs is the proof that regulators are at least taking the science seriously.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (1% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for LGVN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter revenue hit $834K, but the bigger truth is that losses still dwarf the sales base.
Revenue rose 509% vs. prior year to $834K, and gross margin reached 65.5%. But EPS was -$1.07 in the latest quarter, while quarterly 2024 EPS history still showed losses of -$1.61, -$1.83, -$0.34, and -$0.42.
$834K
rev (q)
-$1.07
eps (q)
65.5%
gross margin (q)
the number that mattered
The number that mattered was $834K of quarterly revenue, because even a 509% jump still leaves the company at less than $1M in quarterly sales.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
LGVN is a one-main-program story with roughly $2M in annual revenue. That means bad clinical data and financing stress are not separate risks. They can arrive together.
med
Lomecel-B fails to deliver
This is the quiet part loud. If the lead program disappoints, there is no large operating business underneath to cushion the blow. The stock stops being a biotech option on success and starts trading like a cash question.
impact: the market can reprice a single-asset biotech brutally when the main dataset breaks the thesis
med
cash burn leads to dilution before proof arrives
Negative $2.62 EPS, trailing revenue of $1.44M, and a C++ balance sheet are not a relaxed combination. If timelines slip, new capital usually shows up at a bad time and at a worse price.
impact: your ownership stake gets smaller before the science gets a fair read
med
good unit economics do not scale into a good business
The latest quarter in the hero block shows ~65.5% gross margin; a higher TTM gross in some feeds does not change the tiny sales base. On ~$2M FY-scale revenue here, margin mostly says the little revenue that exists is not structurally broken—it does not prove a durable model.
impact: investors can overread one decent margin number and underread the tiny base underneath it
What would make this risk view less harsh: Lomecel-B becomes the main source of proof, and financing stops being the first question you ask after reading the page. Right now, that has not happened.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next company update
The next filing or business update matters because this story still lives on sequencing: science first, financing second, sentiment third. If management reverses that order, you will feel it.
trend
Lomecel-B becomes the headline for the right reason
This is the card that matters most. You want the stock talking more about program proof and less about survival math. Same company. Very different outcome.
risk
dilution risk before the next big catalyst
With ~$2M FY revenue on this page and negative EPS, your main balance-sheet question is simple: does the company reach the next meaningful proof point without asking shareholders for more?
metric
revenue above the current $2M estimate
$2M is the number on the page. If that stays microscopic, the equity story stays almost entirely clinical. If it moves higher with cleaner execution, the debate gets a little less binary.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, nobody has a clean consensus worth leaning on.
risk profile
volatile
a 5 / 100 price stability score tells you this will not trade like a calm, liquid compounder.
chart momentum
catalyst-driven
this stock is more likely to move on program headlines and financing expectations than on a neat technical trend.
earnings predictability
40 / 100
when revenue is this small and losses are this central, quarterly numbers can shift the story more than they would at a mature company.
source: institutional data
Institutional activity
institutional ownership data for LGVN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive